Zacks: Brokerages Anticipate Horizon Pharma PLC (HZNP) Will Announce Earnings of $0.22 Per Share

Equities analysts expect that Horizon Pharma PLC (NASDAQ:HZNP) will report earnings of $0.22 per share for the current quarter, according to Zacks. Two analysts have issued estimates for Horizon Pharma’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.24. Horizon Pharma posted earnings per share of $0.66 during the same quarter last year, which would indicate a negative year over year growth rate of 66.7%. The firm is scheduled to announce its next quarterly earnings report on Monday, February 26th.

On average, analysts expect that Horizon Pharma will report full-year earnings of $1.09 per share for the current financial year, with EPS estimates ranging from $1.04 to $1.13. For the next financial year, analysts expect that the company will report earnings of $1.30 per share, with EPS estimates ranging from $1.04 to $1.42. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Horizon Pharma.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $271.60 million during the quarter, compared to analysts’ expectations of $259.74 million. Horizon Pharma had a negative net margin of 23.55% and a negative return on equity of 25.30%. The company’s revenue for the quarter was up 30.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 earnings per share.

A number of research analysts have recently issued reports on HZNP shares. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Monday, January 8th. Mizuho upgraded shares of Horizon Pharma from a “neutral” rating to a “buy” rating and lifted their target price for the company from $12.00 to $18.00 in a research note on Friday, January 12th. BidaskClub upgraded shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. ValuEngine cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Jefferies Group lifted their target price on shares of Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Horizon Pharma has an average rating of “Buy” and an average price target of $19.25.

Hedge funds have recently bought and sold shares of the stock. Advantage Investment Management LLC raised its position in Horizon Pharma by 164.8% in the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 4,900 shares during the last quarter. Family Management Corp bought a new position in Horizon Pharma in the 2nd quarter worth approximately $131,000. Brown Advisory Inc. bought a new position in Horizon Pharma in the 3rd quarter worth approximately $145,000. Prudential Financial Inc. raised its position in Horizon Pharma by 5.0% in the 2nd quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 830 shares during the last quarter. Finally, Amalgamated Bank raised its position in Horizon Pharma by 4.8% in the 2nd quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 943 shares during the last quarter. Hedge funds and other institutional investors own 86.58% of the company’s stock.

Horizon Pharma (NASDAQ:HZNP) opened at $15.04 on Monday. The company has a market cap of $2,460.00, a PE ratio of -4.95, a price-to-earnings-growth ratio of 0.70 and a beta of 1.30. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. Horizon Pharma has a one year low of $9.45 and a one year high of $17.69.

WARNING: “Zacks: Brokerages Anticipate Horizon Pharma PLC (HZNP) Will Announce Earnings of $0.22 Per Share” was first published by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/22/zacks-brokerages-anticipate-horizon-pharma-plc-hznp-will-announce-earnings-of-0-22-per-share.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply